中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2014年
17期
9-11
,共3页
IL-28B%单核苷酸基因多态性%慢性乙型肝炎%干扰素
IL-28B%單覈苷痠基因多態性%慢性乙型肝炎%榦擾素
IL-28B%단핵감산기인다태성%만성을형간염%간우소
IL-28B%Single nucleotide genetic polymorphisms%Chronic hepatitis B%Interferon
目的：探讨IL-28B单核苷酸基因多态性与慢性乙型肝炎（CHB）干扰素疗效的相关性。方法选取300例HBeAg阳性CHB患者，给予聚乙二醇化干扰素α（Peg-INF-α）规范治疗48周后以PCR法对IL-28B SNP rs12979860及IL-28B SNP rs8099917基因分型进行检测。结果治疗后HBV DNA定量、ALT、AST水平明显较治疗前下降（P＜0.05），HBeAg转移率53.13%，随访1年后应答率49.44%；Peg-INF-α应答患者与非应答患者IL-28B SNP rs12979860基因型CC、CT、TT分布及等位基因C、T频率比较差异无统计学意义（P＞0.05），IL-28B SNP rs8099917基因型TT、TG分布及等位基因T、G频率比较差异具有统计学意义（P＜0.05）。结论 IL-28B SNP rs8099917可能对干扰素治疗的应答反应性形成影响，其中等位基因G的频率升高可能提示着干扰素的成功应答，因而检测IL-28B SNP rs8099917对干扰素治疗的CHB患者治疗疗效有一定预测价值。
目的：探討IL-28B單覈苷痠基因多態性與慢性乙型肝炎（CHB）榦擾素療效的相關性。方法選取300例HBeAg暘性CHB患者，給予聚乙二醇化榦擾素α（Peg-INF-α）規範治療48週後以PCR法對IL-28B SNP rs12979860及IL-28B SNP rs8099917基因分型進行檢測。結果治療後HBV DNA定量、ALT、AST水平明顯較治療前下降（P＜0.05），HBeAg轉移率53.13%，隨訪1年後應答率49.44%；Peg-INF-α應答患者與非應答患者IL-28B SNP rs12979860基因型CC、CT、TT分佈及等位基因C、T頻率比較差異無統計學意義（P＞0.05），IL-28B SNP rs8099917基因型TT、TG分佈及等位基因T、G頻率比較差異具有統計學意義（P＜0.05）。結論 IL-28B SNP rs8099917可能對榦擾素治療的應答反應性形成影響，其中等位基因G的頻率升高可能提示著榦擾素的成功應答，因而檢測IL-28B SNP rs8099917對榦擾素治療的CHB患者治療療效有一定預測價值。
목적：탐토IL-28B단핵감산기인다태성여만성을형간염（CHB）간우소료효적상관성。방법선취300례HBeAg양성CHB환자，급여취을이순화간우소α（Peg-INF-α）규범치료48주후이PCR법대IL-28B SNP rs12979860급IL-28B SNP rs8099917기인분형진행검측。결과치료후HBV DNA정량、ALT、AST수평명현교치료전하강（P＜0.05），HBeAg전이솔53.13%，수방1년후응답솔49.44%；Peg-INF-α응답환자여비응답환자IL-28B SNP rs12979860기인형CC、CT、TT분포급등위기인C、T빈솔비교차이무통계학의의（P＞0.05），IL-28B SNP rs8099917기인형TT、TG분포급등위기인T、G빈솔비교차이구유통계학의의（P＜0.05）。결론 IL-28B SNP rs8099917가능대간우소치료적응답반응성형성영향，기중등위기인G적빈솔승고가능제시착간우소적성공응답，인이검측IL-28B SNP rs8099917대간우소치료적CHB환자치료료효유일정예측개치。
ObjectiveTo explore the correlation between IL-28B single nucleotide polymorphism and effectiveness of interferon in chronic hepatitis B (CHB).Methods 300 cases of HBeAg positive patients with CHB were selected, and given pegylated interferon alpha (Peg-INF-a) standard treatment. The IL-28B SNP rs12979860 and IL-28B SNP rs8099917 genotyping were tested with PCR method after treatment of 48 weeks.Results HBV DNA quantification, ALT and AST levels after treatment decreased significantly compared with before treatment (P<0.05), HBeAg metastasis rate was 53.13%, response rate after a year of follow-up was 49.44%; the differences were no statistical significant in genotype CC, CT, TT distribution of IL-28B SNP rs12979860 and C, T frequency of allele between Peg-INF-a responder patients and non Peg-INF-a responder patients (P>0.05), the differences were statistical significant in genotype TT, TG distribution of IL-28B SNP rs8099917 and T, G frequency of allele (P<0.05). ConclusionIL-28B SNP rs8099917 may impact the formation of response to interferon treatment, including increased frequency of allele G could prompt the success of the interferon response, thus detecting IL-28B SNP rs8099917 to effectiveness of interferon treatment in CHB patients has certain predictive value.
